Search

Your search keyword '"Schwartz Stefan"' showing total 841 results

Search Constraints

Start Over You searched for: Author "Schwartz Stefan" Remove constraint Author: "Schwartz Stefan"
841 results on '"Schwartz Stefan"'

Search Results

1. Measurable residual disease quantification in adult patients with KMT2A-rearranged acute lymphoblastic leukemia

2. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

6. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

7. Molecular monitoring of minimal residual disease in two patients with MLL-rearranged acute myeloid leukemia and haploidentical transplantation after relapse

8. An intron 9 containing splice variant of PAX2

9. No genetic evidence for involvement of Deltaretroviruses in adult patients with precursor and mature T-cell neoplasms

10. Developmental trajectories and cooperating genomic events define molecular subtypes of BCR::ABL1-positive ALL

11. UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatment

17. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia

23. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma

24. Reply to: Comment on: A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high‐dose methotrexate therapy in open‐label trials

25. Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT)

29. P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA

30. P355: FAVORABLE OUTCOME OF PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH IMATINIB, DOSE-REDUCED INDUCTION FOLLOWED BY ALLOGENEIC STEM CELL TRANSPLANTATION –RESULTS FROM THE GMALL TRIAL 08/13

34. PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia

35. Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications

36. Epidemiology of invasive aspergillosis and azole resistance in patients with acute leukaemia: the SEPIA Study

37. Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia

41. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

43. Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures

46. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

47. Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study

48. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

49. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

Catalog

Books, media, physical & digital resources